Analysis PROCTER & GAMBLE HEALTH LIMITE (PGHL)
6/1/2024
Analysis of PROCTER & GAMBLE HEALTH LIMITE (PGHL)
Procter & Gamble Health Limited (PGHL) has shown some volatility in its stock price recently. The Relative Strength Index (RSI) values have been fluctuating around the 50 mark, indicating a balanced market sentiment between buying and selling pressure.The Moving Average Convergence Divergence (MACD) indicator has been showing positive values, suggesting a potential bullish trend. However, the MACD histogram has been fluctuating, indicating some uncertainty in the trend direction.
Overall, the stock price has been moving within a range, with some resistance levels around 4820 and support levels around 4730. Traders and investors may want to closely monitor these levels for potential breakout or reversal signals.
It is important to consider other factors such as market conditions, news, and sector performance before making any trading decisions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating good financial performance. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 31, 2024. The company shows a solid return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price summary shows a beta value, moving averages, and the range of the stock price over the past fifty-two weeks.
Valuation metrics reveal the company's price-to-earnings ratios, enterprise value, price-to-book ratio, price-to-sales ratio, and market capitalization.
Lastly, dividends and splits information includes details about dividend rates, payout ratios, dividend dates, and historical stock splits.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:- 2020: $274,515,000,000
- 2021: $365,817,000,000
- 2022: $394,328,000,000
- 2023: $383,285,000,000
From these numbers, we can observe that the company has experienced a steady increase in revenue from 2020 to 2022, with a slight decrease in 2023. This indicates a positive revenue growth trend over the years, although there was a slight dip in the most recent fiscal year.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its peak in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with some fluctuations in different areas that may require further analysis.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS), we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. Looking ahead to the next quarter ending on September 30, 2024, analysts project an average EPS of $1.42, ranging from $1.33 to $1.51. This is higher than the EPS of $1.35 reported in the corresponding quarter last year.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.10, with a low estimate of $5.95 and a high estimate of $6.41. This reflects growth from the EPS of $5.67 in the previous fiscal year.
4. Moving on to the next fiscal year ending on September 30, 2025, analysts anticipate an average EPS of $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This shows a further increase from the EPS of $6.10 in the current fiscal year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, indicating growth in both the quarterly and annual performance over the specified periods.
Revenue estimate
Based on analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest that the company has been experiencing strong growth in the past, but analysts expect the growth rate to moderate slightly in the coming years, although it is still expected to be robust.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a wide range of opinions on the future price of the security, with the low end at $164, the high end at $250, and the average at $202.26. The current price is $191.57, which is below the median and average forecast. Investors should consider these different perspectives when making decisions about buying or selling the security.
MACD of PGHL
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
